SCHEMBL2865409

SCHEMBL2865409

COc1ccc(Cn2c(=O)c3c(N)n(-c4ccc(Oc5ccccc5)cc4)nc3c3cc(OC)c(OC)cc32)cc1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.41
RXFP1 Q9HBX9 2/20 0.40
TP53 P04637 2/20 0.40
TSHR P16473 1/20 0.39
ADORA3 P0DMS8 1/20 0.39
P2RX4 Q99571 1/20 0.39
BLM P54132 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
EDNRB P24530 1/20 0.39
EDNRA P25101 1/20 0.39
MAPT P10636 1/20 0.39
KMT2A Q03164 1/20 0.39
GABRA5 P31644 1/20 0.39
PIK3CD O00329 1/20 0.39
ALDH1A1 P00352 1/20 0.38
POLB P06746 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2861196 0.95 MAPK1 (0.42) KDM4ERXFP1TP53TSHRADORA3
SCHEMBL2868756 0.91 KMT2A (0.48) TP53TSHRP2RX4SMN1; SMN2MAPT
SCHEMBL2865359 0.88 ADORA3 (0.39) KDM4EADORA3P2RX4BLMSMN1; SMN2
SCHEMBL2860751 0.87 P2RX4 (0.44) RXFP1TP53P2RX4BLMSMN1; SMN2
SCHEMBL2867619 0.86 BCL2 (0.40) RXFP1ADORA3P2RX4BLMSMN1; SMN2
SCHEMBL2866936 0.85 KMT2A (0.52) TP53TSHRP2RX4SMN1; SMN2MAPT
SCHEMBL2864991 0.85 NPC1 (0.44) KDM4ERXFP1TP53TSHRP2RX4
SCHEMBL13066569 0.84 MGLL (0.44) SMN1; SMN2ALDH1A1
SCHEMBL2856173 0.84 MEN1 (0.41) TP53SMN1; SMN2MAPTKMT2AALDH1A1
SCHEMBL2871092 0.84 P2RX4 (0.54) KDM4ERXFP1TP53TSHRP2RX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
EP-1719771-A1 PYRAZOLOQUINOLONE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-11-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof MAP3K20, MAP4K5, MAP4K3 KDM4E 1057/4885RXFP1 1309/4885TP53 2049/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.